In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli

J Microbiol Immunol Infect. 2021 Dec;54(6):1118-1121. doi: 10.1016/j.jmii.2020.08.018. Epub 2020 Sep 9.

Abstract

Background: Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria.

Methods: Arbekacin minimum inhibitory concentration (MIC) values were determined for 296 drug-resistant Gram-negative bacilli, and compared to previously determined plazomicin, amikacin, gentamicin, and tobramycin MIC values.

Results: The MIC values required to inhibit 50% and 90% of isolates (MIC50 and MIC90, respectively) were 16 and >128 μg/ml, respectively.

Conclusions: Arbekacin showed similar MIC50 values to amikacin and gentamicin, a lower MIC50 value than tobramycin, and a higher MIC50 value than plazomicin.

Keywords: Arbekacin; Enterobacterales; Multidrug-resistant gram-negative bacilli.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Dibekacin / analogs & derivatives*
  • Dibekacin / pharmacology
  • Drug Resistance, Multiple, Bacterial / drug effects*
  • Gram-Negative Bacteria / drug effects*
  • Gram-Negative Bacteria / isolation & purification
  • Gram-Negative Bacterial Infections / microbiology
  • Humans
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Dibekacin
  • arbekacin